MEDICINOVA INC. - COM

NetDania - New 12 months Low: MEDICINOVA INC. - COMMON STOCK

06 Dec 2023 10:34:44 By NetDania Notify

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

19 Nov 2023 17:00:00 By Nasdaq GlobeNewswire

MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

27 Oct 2023 00:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

10 Oct 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Receives Gene Therapy Milestone Payment

04 Oct 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

27 Sep 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

17 Aug 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe

16 Aug 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe

15 Aug 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe

14 Aug 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

29 Jun 2023 05:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe

14 May 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada

30 Apr 2023 18:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

09 Mar 2023 17:00:00 By Nasdaq GlobeNewswire

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

20 Feb 2023 17:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

08 Feb 2023 17:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

30 Jan 2023 17:00:00 By Nasdaq GlobeNewswire

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

12 Jan 2023 17:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

10 Jan 2023 21:00:00 By Nasdaq GlobeNewswire

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

09 Jan 2023 21:00:00 By Nasdaq GlobeNewswire